Education
About Us
Working with TipRanks
Follow Us
Armata Pharmaceuticals Inc (ARMP)
:ARMP
ARMP Stock Chart & Stats
$7.82
$0.11(5.39%)
At close: 4:00 PM EST
$7.82
$0.11(5.39%)
Day’s Range― - ―
52-Week Range$0.90 - $16.34
Previous CloseN/A
Volume48.90K
Average Volume (3M)536.86K
Market Cap
$284.70M
Enterprise Value$448.90M
Total Cash (Recent Filing)$14.76M
Total Debt (Recent Filing)$177.68M
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Mar 19, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.74
Shares Outstanding36,406,906
10 Day Avg. Volume121,090
30 Day Avg. Volume536,864
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-1.39
Price to Sales (P/S)12.93
P/FCF Ratio-1.70
Enterprise Value/Market Cap1.58
Enterprise Value/Revenue88.82
Enterprise Value/Gross Profit126.06
Enterprise Value/Ebitda-14.78
Forecast
1Y Price Target
$12.00Price Target Upside53.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy ProfilePhase 2 results showed AP‑SA02 added to standard antibiotics produced improved clinical outcomes with no evidence of relapse and a favorable safety profile, supporting potential use as a frontline adjunct in difficult Staphylococcus aureus bloodstream infections.
Manufacturing ReadinessCommissioning of an in‑house cGMP phage manufacturing facility and successful initial full production runs demonstrate operational capability to support pivotal trials and potential commercial supply.
Regulatory EndorsementFDA written feedback at an End-of-Phase-2 meeting supports advancing AP‑SA02 into a superiority-based Phase 3 trial, indicating regulator agreement on study design and a clearer path toward a future marketing application.
Bears Say
Funding And Dilution RiskLimited cash resources increase the likelihood that additional financing will be required to advance clinical programs, which could delay development or cause shareholder dilution if not secured.
Milestone Execution RiskInitiation of the pivotal Phase 3 trial depends on completion of regulatory, manufacturing, and operational milestones, creating execution risk if any of those elements are delayed or incomplete.
Research Objectivity ConcernBusiness relationships between covering firms and the companies they cover can introduce conflicts that may affect the perceived objectivity of analyst research and market interpretation.
Armata Pharmaceuticals News
ARMP FAQ
What was Armata Pharmaceuticals Inc’s price range in the past 12 months?
Armata Pharmaceuticals Inc lowest stock price was $0.90 and its highest was $16.34 in the past 12 months.
What is Armata Pharmaceuticals Inc’s market cap?
Armata Pharmaceuticals Inc’s market cap is $284.70M.
When is Armata Pharmaceuticals Inc’s upcoming earnings report date?
Armata Pharmaceuticals Inc’s upcoming earnings report date is Mar 19, 2026 which is in 36 days.
How were Armata Pharmaceuticals Inc’s earnings last quarter?
Armata Pharmaceuticals Inc released its earnings results on Nov 12, 2025. The company reported -$0.74 earnings per share for the quarter, missing the consensus estimate of -$0.42 by -$0.32.
Is Armata Pharmaceuticals Inc overvalued?
According to Wall Street analysts Armata Pharmaceuticals Inc’s price is currently Undervalued.
Does Armata Pharmaceuticals Inc pay dividends?
Armata Pharmaceuticals Inc does not currently pay dividends.
What is Armata Pharmaceuticals Inc’s EPS estimate?
Armata Pharmaceuticals Inc’s EPS estimate is -0.28.
How many shares outstanding does Armata Pharmaceuticals Inc have?
Armata Pharmaceuticals Inc has 36,406,906 shares outstanding.
What happened to Armata Pharmaceuticals Inc’s price movement after its last earnings report?
Armata Pharmaceuticals Inc reported an EPS of -$0.74 in its last earnings report, missing expectations of -$0.42. Following the earnings report the stock price went down -4.634%.
Which hedge fund is a major shareholder of Armata Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in ARMP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Armata Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
134.55%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-8.88%
Trailing 12-Months
Company Description
Armata Pharmaceuticals Inc
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
ARMP Stock 12 Month Forecast
Average Price Target
$12.00
▲(53.45% Upside)
Technical Analysis
Ownership Overview
0.63% Insiders
1.04% Mutual Funds
0.11% Other Institutional Investors
97.32% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---